Glycopyrronium Bromide 1 Mg/5 Ml Oral Solution

Total Page:16

File Type:pdf, Size:1020Kb

Glycopyrronium Bromide 1 Mg/5 Ml Oral Solution Package leaflet: Information for the Patient Glycopyrronium Bromide 1 mg/5 ml Oral Solution Read all of this leaflet carefully before your of this medicine. This is because of an child starts taking this medicine because it increased risk of other side effects such contains important information for them. as dry mouth, retention of urine and ■ Keep this leaflet. You may need to read it constipation when glycopyrronium bromide again. and similar medicines are taken together. ■ If you have any further questions, ask your Please tell the doctor if your child is taking or doctor or pharmacist. have recently taken: ■ This medicine has been prescribed for your ■ Antidepressants such as amitriptyline, child only. Do not pass it on to others. It clomipramine, lofepramine or imipramine may harm them, even if their signs of (known as tricyclic antidepressants) or illness are the same as your child’s. monoamine oxidase inhibitors (MAOIs) ■ If you get any side effects, talk to your such as phenelzine, moclobemide, doctor or pharmacist. This includes any rasagiline, selegiline or tranylcypromine possible side effects not listed in this ■ Phenothiazines such as chlorpromazine, leaflet. See section 4. fluphenazine, prochlorperazine or What is in this leaflet trifluoperazine, used to treatmental problems or nausea, vomiting or vertigo 1. What Glycopyrronium Bromide oral solution ■ is and what it is used for Antihistamines such as promethazine, used to treat allergies 2. What you need to know before you give ■ Glycopyrronium Bromide oral solution Parasympathomimetics such as carbachol, 3. How to use Glycopyrronium Bromide neostigmine or physostigmine which affect oral solution the transmission of nerve impulses to muscles 4. Possible side effects ■ 5. How to store Glycopyrronium Bromide Corticosteroids such as prednisolone, used oral solution to treat various conditions including asthma and inflammation 6. Contents of the pack and other information ■ Inhaled anaesthetics, given before surgery (including at the dentist) 1. What Glycopyrronium Bromide oral ■ Clozapine or haloperidol, used to treat solution is and what it is used for schizophrenia ■ Nefopam, used to treat acute and chronic This medicine is called Glycopyrronium pain Bromide and belongs to a group of medicines ■ Domperidone or metoclopramide, used to called anticholinergic or antimuscarinic drugs. treat nausea and vomiting It contains the active substance ■ Amantadine or levodopa, used to treat glycopyrronium bromide. Each 5 ml dose of Parkinson’s disease oral solution contains 1 mg of glycopyrronium ■ Memantine, used to treat Alzheimer’s bromide. disease ■ Glycopyrronium Bromide is used to treat ■ Slow-dissolving digoxin tablets, excessive production of saliva (sialorrhoea) disopyramide or atenolol, used to treat in children and adolescents aged 3 years heart problems and older. Sialorrhoea (drooling or excessive ■ Metformin, used to treat type 2 diabetes salivation) is a common symptom of many ■ Glyceryl trinitrate tablets, used to treat diseases of the muscles or nerves. It is angina. These may not dissolve under the mainly caused by poor control of muscles in tongue as well as usual because this the face. Acute sialorrhoea may be medicine can cause a dry mouth associated with inflammation, dental or ■ Topiramate or zonisamide, used to treat mouth infections. Glycopyrronium Bromide epilepsy and to prevent migraines oral solution acts on the salivary glands to ■ Potassium chloride containing solid dose reduce production of saliva. products (see section 2 “Do not give Glycopyrronium Bromide oral solution if”) 2. What you need to know before ■ Anticholinergic medicines. (see section 2 you give Glycopyrronium “Do not give Glycopyrronium Bromide oral Bromide oral solution solution if”) Long term use efficacy and safety of Do not give Glycopyrronium Bromide oral Glycopyrronium Bromide oral solution has not solution if the child: been studied beyond the recommended 24 ■ is allergic (hypersensitive) to glycopyrronium weeks of use. Continued use should be bromide or any of the other ingredients of discussed with the child’s doctor every 3 this medicine (listed in section 6) months to check that Glycopyrronium Bromide ■ has glaucoma (increased pressure in oral solution is still right for the child. the eye) Pregnancy and breastfeeding ■ has a condition called myasthenia gravis which leads to muscle weakness and fatigue Glycopyrronium Bromide oral solution must ■ has an obstruction of the stomach (pyloric not be given if the patient is pregnant or stenosis) or bowel causing vomiting, breastfeeding (see section 2. “Do not give abdominal pain and swelling (paralytic ileus) Glycopyrronium Bromide oral solution if”). ■ has an enlarged prostate gland (prostatic Discuss the need for contraception with the hypertrophy) doctor. ■ is unable to completely empty the bladder Driving and using machines (urinary retention) Glycopyrronium Bromide may make the patient ■ suffers fromchronic end stage kidney feel drowsy or cause their eyesight to become disease and require dialysis blurred and this could interfere with their ■ is pregnant or breastfeeding ability to drive or operate machinery safely. ■ is taking potassium chloride solid dose Do not drive or operate machinery until these products effects have fully cleared. If there is any doubt, ■ is taking anticholinergic medicines ask your doctor for advice. Warnings and precautions Glycopyrronium Bromide oral solution Talk to a doctor or pharmacist before giving contains E420 (sorbitol), E217 and E219 Glycopyrronium Bromide if the child: ■ This medicine contains sorbitol (E420). If ■ has gastric reflux (a condition in which the you have been told by the doctor that your liquid stomach contents backs up into the child has an intolerance to some sugars, gullet) contact the doctor before giving this ■ has ulcerative colitis (a chronic medicinal product. inflammation of the large intestine (colon) ■ This medicine contains sodium propyl which can cause abdominal pain, diarrhoea parahydroxybenzoate (E217) and sodium and bleeding from the back passage) methyl parahydroxybenzoate (E219). These ■ has just had a heart attack or are suffering may cause allergic reactions (possibly from heart disease, irregular heartbeats or delayed) and exceptionally, bronchospasms high blood pressure, because this medicine (a narrowing of the airways). can cause a change to their normal heart ■ This medicinal product contains less than rate 1 mmol sodium (23 mg) per maximum dose, ■ has a condition characterised by a faster i.e. essentially is ‘sodium free’. heartbeat than normal (this can be caused by conditions such as an overactive thyroid gland, heart failure or heart surgery) 3. How to use Glycopyrronium ■ is due to have surgery (including at the Bromide oral solution dentist) during which they will be ‘put to sleep’ using inhalation anaesthesia. This is Always give this medicine exactly as the because this medicine may cause a change doctor has told you. Check with your doctor in their normal heart rhythm or pharmacist if you are not sure. ■ has diarrhoea, especially if they have had This medicine is for oral use only. an ileostomy or colostomy This medicine should be given at least one ■ has a high temperature (fever) or the hour before or two hours after a meal. environmental temperature is high, as this Children and adolescents aged 3 years medicine will reduce the amount they sweat, and older: making it harder for their body to cool down ■ has kidney disease, because this medicine’s The initial dose will be calculated based on the dose may need to be decreased weight of the child. The dose will be decided by ■ has compromised blood brain barrier the doctor, using the table below as a guide, ■ has been told by their doctor that they have and will depend on both the effect of an intolerance to some sugars, because this Glycopyrronium Bromide oral solution and any medicine contains sorbitol side effects the patient is experiencing. Section 4 includes possible side effects related In addition, stop treatment and talk to their to the use of Glycopyrronium Bromide oral doctor if the child is suffering with the solution. These should be discussed with the following: ■ child’s doctor, including those for dose seem unwell with a very fast or very slow increases and decreases, and at any other time heart rate ■ should you be concerned. The child should be constipation monitored at regular intervals to check that ■ pneumonia ■ Glycopyrronium Bromide oral solution is still changes in behaviour the right treatment for them. The doctor will decide if treatment should continue and if there should be a dose Weight Dose Dose Dose Dose Dose reduction, after evaluating any of these events. (kg) Level 1 Level 2 Level 3 Level 4 Level 5 If you are not sure any of the above applies (ml) (ml) (ml) (ml) (ml) to your child, talk to a doctor or pharmacist 13-17 1.5 3 4.5 6 7.5 before giving Glycopyrronium Bromide oral solution. 18-22 2 4 6 8 10 Glycopyrronium Bromide oral solution reduces 23-27 2.5 5 7.5 10 12.5 salivation which can increase the risk of dental disease, therefore teeth should be brushed 28-32 3 6 9 12 15 daily and have regular dental checks. 33-37 3.5 7 10.5 14 15 Children 38-42 4 8 12 15 15 This medicine is not recommended for children younger than 3 years. Talk to a doctor 43-47 4.5 9 13.5 15 15 or pharmacist before taking this medicine or if ≥48 5 10 15 15 15 this medicine has been prescribed for a child less than 3 years. Directions for use Other medicines and Glycopyrronium ■ Give the dose prescribed by your doctor Bromide oral solution to the child three times each day. Tell the doctor or pharmacist if your child is ■ Remove the child-resistant taking, have recently taken, or might take any closure from the bottle. Insert other medicines. This includes medicines you the syringe adaptor with the hole have bought without a prescription. into the neck of the bottle (this ■ If their doctor tells you to give both this may have been done already by medicine and one or more similar the pharmacist).
Recommended publications
  • Stable Pressurised Aerosol Solution Composition of Glycopyrronium Bromide and Formoterol Combination
    (19) TZZ¥¥_T (11) EP 3 384 898 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.10.2018 Bulletin 2018/41 A61K 9/00 (2006.01) A61M 15/00 (2006.01) A61K 31/167 (2006.01) A61K 31/40 (2006.01) (2006.01) (2006.01) (21) Application number: 18171127.6 B65D 83/54 A61K 31/573 A61K 31/54 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (22) Date of filing: 23.12.2014 A61K 9/12 A61K 31/58 A61M 39/22 (2006.01) (84) Designated Contracting States: • COPELLI, Diego AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 43100 PARMA (IT) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • DAGLI ALBERI, Massimiliano PL PT RO RS SE SI SK SM TR 43100 PARMA (IT) Designated Extension States: • USBERTI, Francesca BA ME 43100 PARMA (IT) • ZAMBELLI, Enrico (30) Priority: 30.12.2013 EP 13199784 43100 PARMA (IT) (62) Document number(s) of the earlier application(s) in (74) Representative: Bianchetti Bracco Minoja S.r.l. accordance with Art. 76 EPC: Via Plinio, 63 14825154.9 / 3 089 735 20129 Milano (IT) (71) Applicant: Chiesi Farmaceutici S.p.A. Remarks: 43100 Parma (IT) This application was filed on 08-05-2018 as a divisional application to the application mentioned (72) Inventors: under INID code 62. • BONELLI, Sauro 43100 PARMA (IT) (54) STABLE PRESSURISED AEROSOL SOLUTION COMPOSITION OF GLYCOPYRRONIUM BROMIDE AND FORMOTEROL COMBINATION (57) The invention concerns an aerosol solution lower than the limit of quantification, when stored in ac- composition intended for use with a pressurised metered celerated conditions at 25°C and 60% relative humidity dose inhaler, comprising glycopyrronium bromide and (RH) for 6 months in a can internally coated by a resin formoterol, or a salt thereof or a solvate of said salt, op- comprising a fluorinated ethylene propylene (FEP) poly- tionally in combination with one or more additional active mer.
    [Show full text]
  • Hypersalivation in Children and Adults
    Pharmacological Management of Hypersalivation in Children and Adults Scope: Adult patients with Parkinson’s disease, children with neurodisability, cerebral palsy, long-term ventilation with drooling, and drug-induced hypersalivation. ASSESSMENT OF SEVERITY/RESPONSE TO TREATMENT: Severity of drooling can be assessed subjectively via discussion with patients and their carers/parents and by observation. Amount of drooling can be quantified by measuring the number of bibs required per day and this can also be graded using the Thomas-Stonell and Greenberg scale: • 1 = Dry (no drooling) • 2 = Mild (moist lips) • 3 = Moderate (wet lips and chin) • 4 = Severe (damp clothing) CONSIDERATIONS FOR PRESCRIBING/TITRATION No evidence to support the use of one particular treatment over another. Drug choice is to be determined by individual patient factors. When prescribing/titrating antimuscarinic drugs to treat hypersalivation always take account of: • Coexisting conditions (for example, history of urinary retention, constipation, glaucoma, dental issues, reflux etc.) • Use of other existing medication affecting the total antimuscarinic burden • Risk of adverse effects Titrate dose upward until the desired level of dryness, side effects or maximum dose reached. Take into account the preferences of the patients and their carers/ parents, and the age range and indication covered by the marketing authorisations (see individual summaries of product characteristics, BNF or BNFc for full prescribing information). FIRST LINE DRUG TREATMENT OPTIONS FOR ADULTS
    [Show full text]
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information
    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • West Sussex Health and Social Care NHS Trust
    SUSSEX PARTNERSHIP NHS FOUNDATION TRUST MEDICINES FORMULARY GUIDELINE VERSION 26 RATIFYING GROUP (individual formulary Drugs and Therapeutics Group (DTG) decisions and linked guidelines) DATE PUBLISHED July 2021 NEXT REVIEW DATE July 2023 FORMULARY SPONSOR Chief Medical Officer FORMULARY EDITOR Chief Pharmacist LINKED POLICIES AND GUIDELINES Linked policies and antipsychotic Physical health linked guidelines guidelines • Antipsychotics, guidelines for cardiac • Antipsychotics, prescribing guidelines rhythm screening (ECGs) • Asenapine, prescribing guidelines • Antipsychotics, guidelines for the • Clozapine inpatient and community management of weight gain and team policies metabolic disturbances • Clozapine, protocol for the use of • Metformin, information for GPs on its intramuscular injection use with antipsychotics • Clopixol Acuphase, prescribing • Hyperprolactinaemia, prescribing guideline guidelines on the treatment of • Lurasidone, prescribing guidelines antipsychotic induced symptoms • Perinatal mental health, prescribing • Anticoagulants, prescribing guidelines guidelines • Insulin, prescribing guidelines • Rapid tranquilisation policy • Medicines code Long acting antipsychotic guidelines Anxiolytics and hypnotic guidelines • Long acting antipsychotic injections, • Alcohol and benzodiazepine guidelines for use dependence (adults), prescribing • Aripiprazole long acting injection, guidelines for inpatients • Benzodiazepine as anxiolytics (adults), prescribing guidelines prescribing guidelines • Olanzapine long-acting injection,
    [Show full text]
  • The Use of Oral Glycopyrronium in Palliative Care
    Page 1 of 4 The use of oral glycopyrronium in palliative care April 2019 Summary There is limited information on the use of oral glycopyrronium in palliative care. It has, however, been proposed for use in the management of drooling and paraneoplastic sweating in patients with palliative care needs1. Of note, information available to support the use of oral glycopyrronium to treat excessive respiratory secretions at the end of life is not available – the literature only refers to its use when administered subcutaneously. Glycopyrronium bromide is poorly absorbed from the gastrointestinal tract following oral use which has implications for its dosing. If glycopyrronium is to be used orally the lowest effective dose should be initiated and titrated according to response. The patient should also be monitored for any adverse effects. Mechanism of action Glycopyrronium is an anticholinergic agent which inhibits the acetylcholine activity on smooth muscles and structures innervated by parasympathetic nerves.2,3 Salivation is primarily mediated by parasympathetic innervation of the salivary glands and glycopyrronium competitively inhibits cholinergic receptors in salivary glands and other peripheral tissues, thus indirectly reducing the rate of salivation3. Other effects of glycopyrronium include bronchodilation, decreased volume and acidity of gastric secretions, as well as control of excessive pharyngeal, tracheal and bronchial 2 secretions. Palliative Meds Info: Terms and Conditions The information outlined above is intended for healthcare professionals only. The information outlined above is believed to accurately reflect the medical literature at the time of writing. Healthcare professionals must use their own judgment to determine the accuracy and relevance of the information. See www.olh.ie for full terms and conditions.
    [Show full text]
  • NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Drug
    Quantitative Safety & Epidemiology NVA237 / Glycopyrronium bromide Non-interventional Final Study Report NVA237A2401T Multinational, multi-database drug utilization study of inhaled NVA237 in Europe Author Document Status Final Date of final version 28 April 2016 of the study report EU PAS register ENCEPP/SDPP/4845 number Property of Novartis Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis NIS Report Template Version 2.0 August-13-2014 Novartis Confidential Page 2 Non-interventional study report NVA237A/Seebri® Breezhaler®/CNVA237A2401T PASS information Title Multinational, multi-database drug utilization study of inhaled NVA237 in Europe –Final Study Report Version identifier of the Version 1.0 final study report Date of last version of 28 April 2016 the final study report EU PAS register number ENCEPP/SDPP/4845 Active substance Glycopyrronium bromide (R03BB06) Medicinal product Seebri®Breezhaler® / Tovanor®Breezhaler® / Enurev®Breezhaler® Product reference NVA237 Procedure number SeebriBreezhaler: EMEA/H/C/0002430 TovanorBreezhaler: EMEA/H/C/0002690 EnurevBreezhaler: EMEA/H/C0002691 Marketing authorization Novartis Europharm Ltd holder Frimley Business Park Camberley GU16 7SR United Kingdom Joint PASS No Research question and In the context of the NVA237 marketing authorization objectives application, the Committee for Medicinal Products for Human Use (CHMP) recommended conditions for marketing authorization and product information and suggested to conduct a post-authorization
    [Show full text]
  • Specials and Expensive Liquids Guideline
    Specials and expensive liquids guideline Click on the sub headings below for: A-Z for specials and expensive liquids A-Z eye preparations A-Z skin preparations This guideline contains a list of commonly prescribed medicines and alternative methods of administration for patients with swallowing difficulties, feeding tubes or for patients prescribed unlicensed ‘specials’ medication. Each entry takes into account alternative medicines, formulations, cost and licensing. This list is not exhaustive and will be reviewed and updated accordingly. Equality Statement Derby and Derbyshire Clinical Commissioning Group’s aim is to design and implement guidelines and policies that meet the diverse needs of the populations to be served and the NHS workforce has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. Derby and Derbyshire CCG is committed to ensuring equality of access and non-discrimination, irrespective of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, sex (gender) or sexual orientation. It takes into account current UK legislative requirements, including the Equality Act 2010 and the Human Rights Act 1998, and promotes equality of opportunity for all. This document has been designed to ensure that no-one receives less favourable treatment owing to their personal circumstances. Due Regard In carrying out its functions, the Derbyshire Joint Area Prescribing Committee on behalf of Derby and Derbyshire CCG is committed to having due regard to the Public Sector Equality Duty.
    [Show full text]
  • (Lamas) a New Frontier for COPD and Asthma Treatment
    White Paper Long-Acting Muscarinic Agents (LAMAs) A New Frontier for COPD and Asthma Treatment LAMAs in Asthma and COPD Table of Contents 1. Introduction ............................................................................................. 3 2. Tiotropium Bromide ................................................................................. 4 3. Tiotropium + Olodaterol .......................................................................... 7 4. Aclidinium Bromide ................................................................................. 8 5. Aclidinium + Formoterol (ACLIFORM) ....................................................... 9 6. Glycopyrronium Bromide ....................................................................... 10 © 7. Glycopyrronium Bromide + Indacaterol (ULTIBRO )............................... 11 8. Glycopyrronium Bromide + Formoterol .................................................. 13 9. Umeclidinium ........................................................................................ 13 10. Umeclidinium + Vilanterol ..................................................................... 14 11. Triple Therapy ........................................................................................ 16 12. Conclusions ............................................................................................ 16 13. About the Author ................................................................................... 17 14. About CROMSOURCE ............................................................................
    [Show full text]
  • 208437Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208437Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA 208437 Submission Date 07/29/2016 Submission Type 505(b)(2) Generic Name Glycopyrrolate Inhalation Solution Clinical Pharmacology Reviewers - Bhawana Saluja, Ph.D., Anshu Marathe Ph.D. (Team Leader) OCP Review Team Pharmacometric Reviewers - Chao Liu, Ph.D., Jingyu Yu, Ph.D. (Team Leader) OCP Division Clinical Pharmacology 2 Division of Pulmonary, Allergy, and Rheumatology OND Division Products Applicant Sunovion Respiratory Development Inc. Solution for oral inhalation, each 1 mL unit-dose single- Dosage Form and Strength use vial contains 25 mcg of glycopyrrolate (25 mcg/mL) Inhalation of the contents of one vial (25 mcg/mL strength) Proposed Dosing Regimen twice-daily via a portable nebulizer closed-system (CS) eFlow® nebulizer Relevant IND/NDA IND 110663 Maintenance treatment of airflow obstruction in patients Proposed Indication with chronic obstructive pulmonary disease (COPD) including emphysema and/or chronic bronchitis Table of Contents 1. Executive Summary .............................................................................................................................. 5 1.1. Recommendations ..................................................................................................................................... 5 1.2. Post Marketing Requirement ..................................................................................................................
    [Show full text]
  • Inhaled Bronchodilator – Muscarinic Antagonist Medication
    Inhaled Bronchodilator – Muscarinic Antagonist Medication Inhaled Bronchodilator ~ Muscarinic Antagonist Medication ~ Other names for this medication: Short-Acting: Atrovent – ipratropium bromide Long-Acting: Incruse – umeclidinium Incruse – umeclidinium bromide Seebri – glycopyrronium bromide Spiriva – tiotropium bromide Tudorza – aclidinium bromide How does this medication work? This medication helps the muscles around the bronchial tubes in the lungs to relax. This widens or bronchodilates the tubes and improves breathing. This medication also makes the muscle less likely to contract and narrow the tubes in response to exercise, cold air and irritants such as dust and cigarette smoke. How fast and long does this medication work? Atrovent: This depends on how you are advised to use it. It takes about 5 to 15 minutes to begin working. The effects can last for 4 to 6 hours. Incruse: Begins to work within 30 to 60 minutes. Seebri: Begins to work within 5 to 15 minutes. Spiriva: Begins to work within 30 to 60 minutes. Tudorza: Begins to work within 30 to 60 minutes. Please turn over 1 Inhaled Bronchodilator – Muscarinic Antagonist Medication How much medication do I take and how often? Take this medication on a regular basis as directed by your doctor. While taking this medication you may notice: headache dry mouth bad taste in mouth constipation Dry mouth often goes away. If not, talk to your health care provider about what you can do to help. Consult your doctor if: this medication is less effective than usual you have trouble passing urine If any of these occur, you may need other treatment. PD 6229 (Rev 03-2016) 2 .
    [Show full text]
  • Drug Tariff Price Changes
    Drug tariff February 2017 Top 10 price reductions since January 2017 Medicine Pack size Basic price January 2017 Difference Chloral hydrate 143.3mg/5ml oral solution BP 150 ml £244.25 £274.90 -£30.65 Linezolid 600mg tablets 10 tablet £333.82 £360.06 -£26.24 Doxepin 50mg capsules 28 capsule £154.00 £175.18 -£21.18 Cloral betaine 707mg tablets 30 tablet £138.59 £155.98 -£17.39 Olsalazine 500mg tablets 60 tablet £161.00 £177.10 -£16.10 Budesonide 3mg gastro-resistant modified-release capsules 100 capsule £84.15 £99.00 -£14.85 Olsalazine 250mg capsules 112 capsule £144.00 £158.40 -£14.40 Mesalazine 800mg gastro-resistant tablets 180 tablet £80.75 £95.00 -£14.25 Doxepin 25mg capsules 28 capsule £97.00 £110.34 -£13.34 Methocarbamol 750mg tablets 100 tablet £45.02 £55.80 -£10.78 Top 10 price increases since January 2017 Medicine Pack size Basic price January 2017 Difference Quinagolide 75microgram tablets 30 tablet £55.00 £27.00 £28.00 Ampicillin 500mg capsules 28 capsule £40.30 £20.50 £19.80 Ampicillin 250mg capsules 28 capsule £20.50 £4.52 £15.98 Sulfadiazine 500mg tablets 56 tablet £109.37 £99.57 £9.80 Isocarboxazid 10mg tablets 56 tablet £197.95 £188.95 £9.00 Menadiol 10mg tablets 100 tablet £185.90 £177.45 £8.45 Atropine 1% eye drops 10 ml £80.34 £73.52 £6.82 Tamoxifen 40mg tablets 30 tablet £38.09 £33.50 £4.59 Ephedrine hydrochloride 30mg tablets 28 tablet £44.46 £40.25 £4.21 Testosterone enantate 250mg/1ml solution for injection ampoules 3 ampoule £79.75 £76.13 £3.62 Page 1 of 6 Top 25 price reductions since November 2016 Medicine Pack
    [Show full text]